Switch to
More onapp

Venus Remedies Ltd

VENUSREM
Health CarePharmaceuticals
SmallcapWith a market cap of ₹274 cr, stock is ranked 1,611
High RiskStock is 3.55x as volatile as Nifty
201.753.40 (-1.66%)

Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Investment Checklist
BasicPro
Go pro! Unlock deeper insights
Health CarePharmaceuticals
SmallcapWith a market cap of ₹274 cr, stock is ranked 1,611
High RiskStock is 3.55x as volatile as Nifty

Key MetricsEdit

PE RatioPE Ratio
6.73
PB RatioPB Ratio
0.62
Dividend YieldDiv. Yield
Sector PESector PE
35.23
Sector PBSector PB
4.30
Sector Div YldSctr Div Yld
0.91%

Forecast & RatingsDetailed Forecast 

Forecast data is currently unavailable for this stock

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

Venus Remedies Limited is engaged in pharmaceutical product manufacturing business. The Company provides formulations and manufactures dosage injectables.

Financial TrendFinancial statements 

2019202020212022327.98375.99600.36606.96-28.58-10.0061.7640.74
Revenue
Profit
Loss
All values in ₹ cr.
See financial statements

Holdings TrendDetailed holdings 

Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Mutual Fund Holding
Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has almost stayed constant

See detailed holdings

Recent NewsAll news 

Hmm, looks like data is unavailable here. Please come back after some time
See all news

Recent EventsAll events 

Closure of trading window 
Announced OnSep 30, 2022

Pursuant to the Code of Conduct adopted by the Company under SEBI (Prohibition of Insider Trading) Regulations, 2015, this is to inform that the trading window for dealing in equity shares of the Company shall remain closed for all Designated Persons of the Company, as defined under the said Regulations, from October 1, 2022, till 48 hours from the declaration of the Unaudited Financial Results for the quarter and half year ending on September 30, 2022. | Download

Pursuant to the Code of Conduct adopted by the Company under SEBI (Prohibition of Insider Trading) Regulations, 2015, this is to inform that the trading window for dealing in equity shares of the Company shall remain closed for all Designated Persons of the Company, as defined under the said Regulations, from October 1, 2022, till 48 hours from the declaration of the Unaudited Financial Results for the quarter and half year ending on September 30, 2022. | Download

Annual General Meeting 
Announced OnAug 24, 2022

Venus Remedies Limited has informed the Exchange about Voting results and Scrutinizer report of Annual General Meeting held on 23-Aug-2022 | Download

Venus Remedies Limited has informed the Exchange about Voting results and Scrutinizer report of Annual General Meeting held on 23-Aug-2022 | Download

Cash Dividend 
Ex. DateSep 23, 2013

Final • Div/Share: ₹ 3

See all events